{"title":"Pneumocystis Pneumonia in Patients With Rheumatic Disorders Receiving Very Low-Dose Trimethoprim-Sulfamethoxazole Prophylaxis.","authors":"Yoshitaka Ueda, Kota Shimada, Naoto Yokogawa","doi":"10.1111/1756-185x.70912","DOIUrl":"https://doi.org/10.1111/1756-185x.70912","url":null,"abstract":"","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"29 10","pages":"e70912"},"PeriodicalIF":2.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149193574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Binit Vaidya, Jose Paulo Lorenzo, Hanna Monica Z Sollano, Manisha Bhochhibhoya, Khabizhanova Venera Bolatovna, Ronaldo De Vera, Ana Monica Estrella, Shweta Nakarmi, Kanon Jatuworapruk, Claire Teo, Rakhma Yanti Hellmi, Paramjeet Singh, Panchalee Satpanich, Mustafa Alhayali, Fariz Yahya, Galymzhan Togizbayev
{"title":"Development and Preliminary Psychometric Validation of the Gout Knowledge, Attitudes and Practices (G-KAP) Questionnaire: An Asia-Pacific Multicenter Study.","authors":"Binit Vaidya, Jose Paulo Lorenzo, Hanna Monica Z Sollano, Manisha Bhochhibhoya, Khabizhanova Venera Bolatovna, Ronaldo De Vera, Ana Monica Estrella, Shweta Nakarmi, Kanon Jatuworapruk, Claire Teo, Rakhma Yanti Hellmi, Paramjeet Singh, Panchalee Satpanich, Mustafa Alhayali, Fariz Yahya, Galymzhan Togizbayev","doi":"10.1111/1756-185x.70931","DOIUrl":"https://doi.org/10.1111/1756-185x.70931","url":null,"abstract":"<p><strong>Aim: </strong>To develop and undertake preliminary psychometric validation of the Gout Knowledge, Attitudes and Practices (G-KAP) Questionnaire for patients with gout in multiple Asia-Pacific clinical settings.</p><p><strong>Methods: </strong>Six development experts and nine relevance experts reviewed the English 56-question instrument. Analyses included 312 baseline participants from 10 countries and 117 paired assessments; 149 participants formed an additional recruitment-wave subset. Language assistance involved oral explanation without a fixed translation script. We evaluated content relevance, keyed knowledge reliability, item-level stability, and exploratory structure using explicit coding and missing-data rules.</p><p><strong>Results: </strong>S-CVI/Ave was 0.998 across 68 rated rows. The 19-indicator knowledge score averaged 56.1% ± 20.3%; KR-20 was 0.770 and common-factor omega 0.764. Absolute-agreement single-measure ICC was 0.763 (95% bootstrap CI 0.635-0.857); mean retest increase was 2.34 percentage points (p = 0.037). Numeric attitude ICCs ranged 0.345-0.838. Among 303 complete cases for 38 exploratory indicators, full-matrix and common-factor parallel analyses suggested 7 and 11 dimensions. The seven-factor comparison model included two weak two-item factors and ambiguous cross-loadings.</p><p><strong>Conclusion: </strong>The English G-KAP shows strong expert-rated relevance and encouraging preliminary knowledge-score reliability. Oral-assistance variability, unequal recruitment and uncertain dimensionality limit interpretation. Cross-cultural validity, measurement invariance, attitude/practice composite scores and clinical effectiveness are unestablished. Standardized administration, linguistic adaptation and independent confirmatory evaluation are needed before cross-country comparison or subscale development.</p>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"29 10","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149267500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aravind Radhakrishnan, Biman Saikia, Aman Sharma, Seema Chhabra
{"title":"Antineutrophil Cytoplasmic Antibodies: Integrating History, Pathogenesis, and Modern Diagnostics.","authors":"Aravind Radhakrishnan, Biman Saikia, Aman Sharma, Seema Chhabra","doi":"10.1111/1756-185x.70910","DOIUrl":"10.1111/1756-185x.70910","url":null,"abstract":"<p><p>Antineutrophil cytoplasmic antibodies (ANCA) define a distinct group of small-vessel vasculitides collectively termed ANCA-associated vasculitis (AAV). Since their initial recognition as immunofluorescence patterns, ANCA have evolved into well-characterized pathogenic autoantibodies directed primarily against proteinase 3 (PR3) and myeloperoxidase (MPO). This review integrates the historical evolution of ANCA discovery with current understanding of disease pathogenesis and contemporary diagnostic practice. We summarize key biological mechanisms underlying AAV, including genetic susceptibility, epigenetic dysregulation, neutrophil priming, complement activation via the alternative pathway, and neutrophil extracellular trap formation, which together drive endothelial injury and necrotizing vasculitis. Recognition of PR3 ANCA and MPO ANCA as pathogenic entities has reshaped disease classification and supports the concept of biologically distinct disease subsets. In parallel, laboratory diagnostics have undergone a major paradigm shift. We critically review the transition from indirect immunofluorescence-first algorithms to immunoassay-first strategies endorsed by the 2017 revised international consensus, highlighting the improved diagnostic performance of contemporary antigen-specific immunoassays. The roles of automated immunofluorescence, biochip mosaic platforms, and multiparametric testing are discussed within harmonized diagnostic workflows. Emphasis is placed on strict clinical gating, quantitative antibody interpretation, and likelihood ratio-based reporting to enhance diagnostic accuracy and reduce false-positive results. By integrating historical, biological, and diagnostic perspectives, this review provides a practical reference framework for evidence-based ANCA testing and interpretation in clinical practice.</p>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"29 10","pages":"e70910"},"PeriodicalIF":2.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149169421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Zhaoxiang Fan, Shi Yu Liu, Angela Marie Li Huan Chan, Li Wearn Koh, Chuanhui Xu
{"title":"Acute Inflammatory Reaction to Mycophenolate Mofetil in a Patient With Systemic Lupus Erythematosus.","authors":"Zhaoxiang Fan, Shi Yu Liu, Angela Marie Li Huan Chan, Li Wearn Koh, Chuanhui Xu","doi":"10.1111/1756-185x.70915","DOIUrl":"https://doi.org/10.1111/1756-185x.70915","url":null,"abstract":"","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"29 10","pages":"e70915"},"PeriodicalIF":2.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149181696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Chikungunya Seropositivity in Rheumatoid Arthritis: The Importance of Clinical Phenotyping and Exposure Context.","authors":"Xinyi Wang, Hongwu Shen","doi":"10.1111/1756-185x.70917","DOIUrl":"https://doi.org/10.1111/1756-185x.70917","url":null,"abstract":"","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"29 10","pages":"e70917"},"PeriodicalIF":2.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149181787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rakesh Kumar Pilania, C. V. Gaythri, Pratap Kumar Patra
{"title":"Medium- To High-Dose Aspirin in Kawasaki Disease: Time to Revisit an Old Tradition","authors":"Rakesh Kumar Pilania, C. V. Gaythri, Pratap Kumar Patra","doi":"10.1111/1756-185x.70897","DOIUrl":"10.1111/1756-185x.70897","url":null,"abstract":"<p>Kawasaki disease (KD) is an acute systemic vasculitis of childhood and remains the leading cause of acquired heart disease in children. The major concern in KD is not the fever or mucocutaneous inflammation alone, but the risk of development of coronary artery lesions (CALs), including coronary artery dilatation and aneurysm formation. The incidence of KD has also increased in developing nations in recent decades, driven by greater awareness among clinicians and improvements in diagnosis. The pathophysiology includes medium-vessel vasculitis, predominantly involving the coronary arteries, with immune activation and endothelial dysfunction. Timely treatment with intravenous immunoglobulin (IVIG) has changed the natural history of the disease and remains the cornerstone of therapy [<span>1</span>].</p><p>Aspirin has been used as an adjunctive agent in KD since the 1970s. Traditionally, it was given in moderate to high doses (30–100 mg/kg/day) during the acute febrile phase for its presumed anti-inflammatory effect, and then continued in low doses (3–5 mg/kg) during the convalescent phase for its antiplatelet effect. North American practice has generally favored high-dose aspirin, usually 80–100 mg/kg/day, while Japanese guidelines and several Asian centres have used a moderate dose of 30–50 mg/kg/day during the acute phase [<span>2</span>].</p><p>This dosing strategy, however, has more historical support than strong trial-based support [<span>3</span>]. Much of the early use of aspirin was based on clinical tradition and retrospective observations rather than on properly controlled trials. The early report by Kato and colleagues in 1979 established aspirin's important role in KD treatment by suggesting fewer CALs with aspirin-containing regimens compared with corticosteroid regimens [<span>4</span>]. However, this study was non-randomized and had important limitations, including possible selection bias and uneven group allocation. Therefore, it could not settle the question of the best aspirin dose.</p><p>In recent decades, the therapeutic paradigm of moderate to high dose aspirin during the acute phase has been subjected to questions regarding its utility as it has been associated with potential adverse effects, including hepatotoxicity, gastrointestinal bleeding, and rarely Reye's syndrome. The debate over the optimal aspirin dosage in KD has intensified recently, and numerous systematic reviews and meta-analyses have examined its efficacy [<span>5-10</span>]. The meta-analyses have assessed the effect of aspirin on the incidence of CALs, efficacy and safety, interactions with IVIg, and differences in population-specific responses.</p><p>The most important outcome of KD treatment is, without question, the prevention of CALs. If high-dose aspirin is to be justified, it should show a clear advantage in reducing CALs. The available literature does not consistently show such a benefit [<span>5-10</span>]. A meta-analysis from China, which included","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"29 10","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1756-185x.70897","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149109466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}